Article info
PDFNeurodegeneration
Original research
CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
- Correspondence to Professor Kathy Keyvani, Institute of Neuropathology, Faculty of Medicine, University of Duisburg-Essen, Essen 45147, Germany; kathy.keyvani{at}uk-essen.de
Citation
CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
Publication history
- Received April 24, 2019
- Revised July 15, 2019
- Accepted July 23, 2019
- First published August 1, 2019.
Online issue publication
December 17, 2019
Article Versions
- Previous version (1 August 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.